1Y Close · As of Aug 26, 2026
DAEWON PHARMACEUTICAL operates in the Pharmaceuticals sector.
Legal name: DAEWON PHARMACEUTICAL CO.,LTD
In fiscal year 2025, DAEWON PHARMACEUTICAL (003220) reported revenue of 605.4 billion KRW, up 1.2% from 598.2 billion KRW a year earlier.
Operating profit was 3.5 billion KRW and net income was -4.0 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 176.7 billion KRW, with a P/B of 0.64.
These figures can be verified in the DART filing (receipt no. 20260318001398).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 605.4B | 3.5B | -4.0B |
| 2024 | 598.2B | 28.2B | 9.0B |
| 2023 | 527.0B | 32.2B | 23.5B |
Recent Filings
Fair Trade Compliance Status (Informational Disclosure)
Semi-Annual Report (2026.06)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-28 | Fair Trade Compliance Status (Informational Disclosure) |
| 2026-08-07 | Semi-Annual Report (2026.06) |